Valdecoxib (Bextra) Associated with Hypersensitivity Reactions
December 13, 2002
Pfizer has changed the labeling for Bextra (valdecoxib) to include warnings about the potential for hypersensitivity reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, and exfoliative dermatitis. Additional information is available at the following links:
- MedWatch Alert:
- Letter to HealthCare Professionals:
December 13, 2002; University of Utah, Drug Information Service. Copyright 2009, Drug Information Service, University of Utah, Salt Lake City, UT.